Evaluation and management of the patient with difficult-to-control or resistant hypertension

American Family Physician

Volumn 79, Issue 10, 2009, Pages 863-869

  Viera, Anthony J ^a   Hinderliter, Alan L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; AMILORIDE; AMLODIPINE; AMLODIPINE BESYLATE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; CLONIDINE; DIURETIC AGENT; EPLERENONE; FUROSEMIDE; GUANFACINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LABETALOL; MINOXIDIL; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; RESERPINE; SPIRONOLACTONE; TERAZOSIN; THIAZIDE DIURETIC AGENT; TORASEMIDE; UNINDEXED DRUG;

BLOOD PRESSURE MEASUREMENT; CHRONIC KIDNEY DISEASE; DEPRESSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLUID RETENTION; GYNECOMASTIA; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; OBESITY; PATIENT ASSESSMENT; PRIMARY HYPERALDOSTERONISM; REVIEW; SLEEP APNEA SYNDROME; WHITE COAT HYPERTENSION;

EID: 67649295428     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49(1):69-75.
2. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States [published correction appears in N Engl J Med. 2002;346(7):544]. N Engl J Med. 2001;345(7):479-486.
3. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006;47(3):345-351. (Pubitemid 43740273)
4. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510-526.
5. U.S. Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md. NIH Publication No. 04-5230. August 2004.
6. Lochner J, Rugge B, Judkins D, Saseen J. Clinical inquiries. How effective are lifestyle changes for controlling hypertension? J Fam Pract. 2006;55(1):73-74. (Pubitemid 43108046)
7. U.S. Department of Health and Human Services. National Heart Lung and Blood Institute. Your guide to lowering your blood pressure with DASH. http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/. Accessed May 15, 2008.
8. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3-10.
9. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium restriction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334(7599):885. (Pubitemid 46724330)
10. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160(1):31-37. (Pubitemid 29054224)
11. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. The rational clinical examination. Is this patient taking the treatment as prescribed? JAMA. 1993;269(21):2779-2781.
12. Viera AJ, Jamieson B, Dealleaume L. Clinical inquiries. How effective are hypertension self-care interventions? J Fam Pract. 2007;56(3):229-231.
13. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med. 1991;151(9):1786-1792.
14. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339(27):1957-1963. (Pubitemid 29024127)
15. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427-1481. (Pubitemid 36776153)
16. Frank J. Managing hypertension using combination therapy. Am Fam Physician. 2008;77(9):1279-1286.
17. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens. 2001;14(12):1263-1269. (Pubitemid 33151484)
18. Verberk WJ, Kroon AA, Kessels AG, et al. The optimal scheme of self blood pressure measurement as determined from ambulatory blood pressure recordings. J Hypertens. 2006;24(8):1541-1548. (Pubitemid 44162455)
19. Pickering TG, White WB, for the American Society of Hypertension Writing Group. ASH Position Paper: Home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens. 2008;2(3):122.
20. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39(5):982-988. (Pubitemid 34547797)
21. Pimenta E, Gaddam KK, Oparil S. Mechanisms and treatment of resistant hypertension. J Clin Hypertens (Greenwich). 2008;10(3):239-244.
22. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289(2):178, and JAMA. 2004;291(18):2196]. JAMA. 2002;288(23):2981-2997.
23. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-3264.
24. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47(3):352-358. (Pubitemid 43740274)
25. Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001;161(22):2661-2667. (Pubitemid 33134841)
26. Fagard RH, Staessen JA, Thijs L, et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med. 2007;167(17):1884-1891. (Pubitemid 47481484)
27. Beckett NS, Peters R, Fletcher AE, et al., for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-1898.
28. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42(5):878-884. (Pubitemid 37413724)
29. Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I, for the Orlistat and Resistant Hypertension Investigators. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002;20(11):2257-2267.
30. Sjöström L, Lindroos AK, Peltonen M, et al., for the Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683-2693.
31. Sjöström L, Narbro K, Sjöström CD, et al., for the Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-752.
32. Grogan JR, Kochar MS. Alcohol and hypertension. Arch Fam Med. 1994;3(2):150-154.
33. Viera AJ, Kshirsagar AV, Hinderliter AL. Lifestyle modification advice for lowering or controlling high blood pressure: who's getting it? J Clin Hypertens (Greenwich). 2007;9(11):850-858.
34. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994;12(5):609-615. (Pubitemid 24192887)
35. Onusko E. Diagnosing secondary hypertension. Am Fam Physician. 2003;67(1):67-74. (Pubitemid 36227387)
36. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685-693. (Pubitemid 30140419)
37. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40(6):892-896. (Pubitemid 35434912)
38. Mosso L, Carvajal C, González A, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161-165. (Pubitemid 36944590)
39. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37(4):699-705. (Pubitemid 32268029)
40. Calhoun DA. Management of hyperaldosteronism and hypercortisolism. In: Izzo JL Jr, Sica DA, Black HR, eds. Hypertension Primer: The Essentials of High Blood Pressure: Basic Science, Population Science, and Clinical Management. 4th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2008:564-567.
41. Chapman N, Dobson J, Wilson S, et al., for the Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839-845.
42. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19(12):2271- 2277. (Pubitemid 33135251)
43. Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation. 2003;107(1):68-73. (Pubitemid 36070935)
44. Saseen JJ, Carter BL, Brown TE, Elliott WJ, Black HR. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension. 1996;28(1):109-114. (Pubitemid 26231098)
45. Townsend RR, DiPette DJ, Goodman R, et al. Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients. Clin Pharmacol Ther. 1990;48(6):665-675.
46. Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med. 2006;355(4):385-392.
47. Mann JF, Schmieder RE, McQueen M, et al., for the ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547-553.